secwatch.observer — SEC 8-K summary
======================================

Issuer:     IRONWOOD PHARMACEUTICALS INC (IRWD)
CIK:        0001446847
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001104659-24-001989
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ironwood guides FY2024 adj EBITDA >$150M, LINZESS low-single digit growth, pipeline catalysts
--------------------------------------------------------------------------------

- Maintains FY2023 guidance: LINZESS net sales growth 6-8%, revenue $435-450M, adjusted EBITDA ~($900M) from VectivBio charge.
- FY2024 guidance: LINZESS U.S. net sales low-single digit % growth, total revenue $435-455M, adjusted EBITDA >$150M.
- Expects apraglutide STARS Phase 3 topline data in SBS-IF in March 2024; CNP-104 Phase 2 topline data in PBC in Q3 2024.
- High-single digit LINZESS prescription demand growth in 2024 offset by mid-to-high single digit price erosion from Medicaid AMP cap removal.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1446847/000110465924001989/0001104659-24-001989-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1446847/000110465924001989/tm242140d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-001989

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer